Thanks Piton72 - the Pitt Hopkins newsletter was really informative. The clinical trials section shows how quickly the competitive landscape is evolving in the space.
Also, the “Pitt Hopkins-like Syndrome 1 & 2” was new to me. We have a long way to go but it would be great to think that NNZ-2591 may help these patients as well down the track.
Have a great weekend.
- Forums
- ASX - By Stock
- Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.54%
!
$12.92

Thanks Piton72 - the Pitt Hopkins newsletter was really...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.92 |
Change
0.070(0.54%) |
Mkt cap ! $1.626B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.85 | $6.608M | 504.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 556 | $12.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.92 | 1094 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 143 | 12.940 |
4 | 765 | 12.930 |
7 | 2516 | 12.920 |
6 | 1929 | 12.910 |
9 | 3740 | 12.900 |
Price($) | Vol. | No. |
---|---|---|
12.950 | 2905 | 14 |
12.960 | 1219 | 15 |
12.970 | 1019 | 7 |
12.980 | 2414 | 10 |
12.990 | 2796 | 11 |
Last trade - 15.40pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online